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Abstract
The treatment of patients with serious Gram-negative infections
must be both prompt and correct. Numerous studies have
demonstrated that mortality risk is significantly increased when the
initial antibiotic regimen does not adequately cover the infecting
pathogen. Furthermore, changing to an appropriate regimen once
culture results are available does not reduce this risk. Therefore,
one must empirically treat serious infections with a regimen that
covers likely pathogens. Selecting such a regimen is complicated
by the increasing prevalence of resistance to commonly used anti-
biotics. Moreover, multidrug-resistant pathogens, once limited to
hospital-acquired infections, are increasingly being detected in
community-acquired infections, especially those involving the
urinary and gastrointestinal tracts or in immunocompromised
patients. Consequently, the initial antibiotic regimen must have a
broad spectrum of activity that includes potential resistant
pathogens, as indicated by the local antibiogram. Many multidrug-
resistant pathogens remain susceptible to carbapenems despite
increasing worldwide antibiotic resistance. This article reviews the
role played by carbapenems in the initial treatment of serious
Gram-negative infections and the potential effect of emerging
resistance on this role.
Introduction
Appropriate antibiotic therapy for any given circumstance
requires consideration of three factors: the pathogen, the
timing, and the patient, including the site of infection. The role
of the pathogen is clearly understood. Treatment must be
directed at the pathogens potentially responsible for the
patient’s illness, and this treatment must take into considera-
tion local resistance factors for these pathogens. In serious
bacterial infections such as bacteremia and ventilator-
associated pneumonia (VAP), antibiotic resistance is the
most important risk factor for therapeutic failure [1,2]. In a
prospective, multicenter evaluation [2], 19% of Klebsiella
pneumoniae bacteremias were caused by organisms that
produced extended-spectrum β-lactamase (ESBL). Twenty-
four per cent of these patients died within 14 days of the first
positive blood culture. The single greatest risk factor for
mortality was failure to use an antibiotic with in vitro activity
against the isolate during the initial 5 days (odds ratio 10.7,
95% confidence interval 2.2 to 57.0; P = 0.001).
Although less often appreciated than the pathogen, the
significance of therapeutic timing is equally important. In the
study described above, reduced mortality was associated not
only with appropriate antimicrobial therapy but also with the
initiation of this therapy early in the course of the disease
process. Likewise, several evaluations of both VAP (Figure 1)
[3-6] and septicemia (Figure 2) [7-10] have demonstrated that
inadequate initial antibiotic therapy was associated with
increased mortality risk. In one evaluation [11], 73% of
patients with VAP received an initial empiric antibiotic
regimen that was inappropriate for their infection based on
subsequent culture results. In multivariate analysis, this
inappropriate antibiotic selection was a significant and
independent risk factor for in-hospital mortality (odds ratio
3.28, 95% confidence interval 2.12 to 5.06; P = 0.006). In
another evaluation of patients with VAP [5], inappropriate
initial antibiotic therapy was associated with a 2.4-fold
increase in mortality risk (95% confidence interval 1.5-fold to
5.0-fold). Furthermore, changing from inappropriate to
appropriate therapy once culture results were available did
not reduce this risk significantly. Consequently, in order to
reduce mortality, it is essential that the initial antibiotic
regimen appropriately cover likely pathogens [8,12]. There-
fore, the initial 12 to 24 hours of therapy is not a time to be
concerned with restricting antibiotics.
Patient status also influences the prognosis and therefore the
treatment approach. Patients with prolonged hospitalization,
prior antibiotic use, or higher Acute Physiology and Chronic
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Health Evaluation II scores are more likely to be infected with
resistant organisms [1]. In addition, mortality risk has been
shown to correlate significantly and independently with Acute
Physiology and Chronic Health Evaluation II score [8].
Excepting critically ill patients with short life expectancies, the
detrimental effect of inadequate initial antibiotic coverage
increases with increasing severity of disease [12].
Although the initial antibiotic regimen should be broad
enough to cover likely pathogens, this regimen should be
rapidly de-escalated after 48 to 72 hours, with subsequent
antibiotic therapy determined by culture results and clinical
course. In a prospective evaluation of patients with VAP [13]
the use of broad initial coverage with a combination of
imipenem, ciprofloxacin, and vancomycin, with modification
after 24 to 48 hours, significantly increased the prevalence of
adequate initial coverage (94% versus 48%; P < 0.01),
reduced the duration of therapy (9 days versus 15 days;
P < 0.001), and decreased recurrences (8% versus 24%;
P = 0.03). A prospective randomized trial of intensive care
unit patients with pulmonary infiltrates [14] evaluated the
effects of a protocol of de-escalation of antibiotic therapy
after 3 days, based on clinical status. This protocol resulted in
a shorter duration of treatment (mean 3 days versus 10 days;
P < 0.0001), a lower cost of antibiotic therapy (mean $259
versus $640; P < 0.0001), and reduced prevalence of
resistance and/or superinfection (15% versus 35%; P= 0.017)
compared with ‘standard’ therapy. However, there was no
significant effect on mortality (0% for de-escalation versus
7% for standard therapy; P > 0.05).
Optimal dosing is a critical component of antibiotic therapy,
regardless of type or class of agent employed. In patients
with serious bacterial infections, the use of maximum
tolerable antibiotic doses improves therapeutic outcomes and
may prevent the development of resistance [15,16]. Bacteri-
cidal rather than bacteriostatic agents may be preferred,
because these agents may curtail the development of resis-
tance. As Stratton so concisely stated, ‘Dead bugs don’t
mutate’ [17]. However, even when bactericidal agents are
used, the administered dose must be sufficient to achieve
bactericidal activity. In a Monte Carlo simulation, the
probability of achieving bactericidal activity against represen-
tative pathogens of nosocomial pneumonia (excluding
methicillin-resistant Staphylococcus aureus) increased from
67.9% to 92.5% when the ceftazidime dose was doubled
from 3 to 6 g/day, from 90.3% to 95.0% when the cefepime
dose was doubled from 2 to 4 g/day, and from 12.0% to
54.7% when the ciprofloxacin dose was increased by 50%
from 800 to 1,200 mg/day [18]. In the same study the
probability of achieving bactericidal activity for a typical
carbapenem regimen was approximately 98%, illustrating the
potency of this class against Gram-negative infections.
Considering the therapeutic principles summarized above,
this article reviews the rationale for carbapenem use in the
initial therapy of serious bacterial infections that are poten-
tially caused by Gram-negative pathogens. It also explores
the potential effects of emerging resistance on carbapenem
use.
Carbapenem resistance mechanisms
Activity against many multidrug-resistant (MDR) pathogens is
among the main advantages of using carbapenems in
patients with serious Gram-negative infections. Consequently,
the future utility of carbapenems depends, to a great extent,
on controlling the development of resistance to this class.
Figure 1
Adequate versus inadequate initial antibiotic therapy: intensive care
unit (ICU)-acquired pneumonia and ventilator-associated pneumonia
(VAP). Shown is the mortality risk associated with adequate versus
inadequate initial antibiotic therapy in patients with ICU-acquired
pneumonia [3] or VAP [4-6].
Figure 2
Adequate versus inadequate initial antibiotic therapy: bacteremia and
severe sepsis/early septic shock. Shown is the mortality risk
associated with adequate versus inadequate initial antibiotic therapy in
patients with bacteremia [8-10] or severe sepsis/early septic shock [7].Page 3 of 7
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Antibiotic resistance is a function of drug exposure and can
be acquired through numerous mechanisms [19-21].
Resistance to carbapenems in particular is produced through
three mechanisms: reduced permeability, efflux, and synthe-
sis of carbapenem β-lactamases.
Reduced permeability is the major mechanism by which
Pseudomonas aeruginosa acquires resistance to carba-
penems in the Western hemisphere. To be effective against
Gram-negative organisms, carbapenems must enter the
periplasmic space. Downregulation of porin channels in the
outer lipopolysaccharide membrane effectively reduces this
entry. Recent data suggest that reduced permeability, in
combination with certain β-lactamases, may also play a role in
resistance acquisition by Klebsiella,  Enterobacter, and
Acinetobacter spp. [22-24].
Carbapenem β β-lactamases
Synthesis of β-lactamases by Gram-negative bacilli has become
increasingly important in the development of resistance to
carbapenems. Four classes of β-lactamases can produce
carbapenem resistance (Table 1). Traditionally, carbapenemase-
mediated resistance, particularly in Pseudomonas and
Acinetobacter spp., was due to the synthesis of class-B
metallo-β-lactamases. Although widely scattered throughout
the world, bacteria possessing genes for metallo-β-lacta-
mases have not yet penetrated North America to any great
extent. Thus, carbapenems could be used with relatively little
concern about β-lactamase induced resistance. However, the
recent emergence of carbapenem-resistant organisms
utilizing other classes of β-lactamase has altered this
presumption. A chromosomal ‘AmpC-like’ β-lactamase that
can be transferred from one organism to another via plasmids
has been recognized in Klebsiella,  Enterobacter,  Pseudo-
monas, and Acinetobacter spp., which utilize this mechanism
in combination with a permeability defect to create carba-
penem resistance [25]. In addition, an increasing number of
organisms, most notably Acinetobacter spp., can produce
oxacillinase enzymes that inactivate carbapenems [26].
Finally, in 2001, Yigit and colleagues [27] reported isolation
of a K. pneumoniae strain that possessed a novel plasmid-
encoded class A β-lactamase (K. pneumoniae carbapene-
mase [KPC]-1), which conferred resistance to imipenem, mero-
penem, extended-spectrum cephalosporins, and aztreonam
[27]. Several other KPCs have been identified since.
Furthermore, this class of enzymes is no longer limited to
Klebsiella but also has recently been found in Escherichia
coli,  Salmonella enterica,  Citrobacter freundii,  Serratia
marcescens, and P. aeruginosa [28,29].
Emergence of resistance in P. aeruginosa
In a cohort evaluation of hospitalized patients, the likelihood
of emergence of antibiotic-resistant P. aeruginosa was
greatest in patients treated with imipenem (hazard ratio 2.8;
P = 0.02), followed by piperacillin (hazard ratio 1.7; P = 0.3),
ciprofloxacin (hazard ratio 0.8; P = 0.6), and ceftazidime
(hazard ratio 0.7; P = 0.4) [30]. Similarly, in an open, pros-
pective evaluation of intensive care unit patients, the risk for
emergence of resistance was greatest in patients treated with
imipenem (hazard ratio 6.0, 95% confidence interval 2.8 to
13.2; P < 0.0001), followed by piperacillin-tazobactam (hazard
ratio 3.8, 95% confidence interval 1.2 to 11.8; P = 0.018)
and ceftazidime (hazard ratio 1.1, 95% confidence interval
0.3 to 3.9; P = 0.85) [31]. Likewise, cumulative data from
studies of patients with P. aeruginosa pneumonia who were
treated with imipenem suggest a high rate of emergence of
resistance during therapy (Table 2) [32-38]. Fear of central
nervous system toxicity has caused many clinicians to limit
their dosing of imipenem to 2 g/day, even in the presence of
normal renal function. The use of maximum doses of antibiotic
may limit the development of resistance, particularly that
which is mediated by chromosomal mechanisms.
Decreased permeability is sufficient for the acquisition of
resistance to imipenem by P. aeruginosa. In contrast, the
acquisition of resistance to newer carbapenems requires
Available online http://ccforum.com/content/12/S4/S5
Table 1
Carbapenem β β-lactamases
β-Lactamase Organisms
Class A: KPC 1 to 4 Klebsiella, Escherichia coli, 
Enterobacter, Salmonella, 
Pseudomonas
Class B: metallo-β-lactamases Pseudomonas, Acinetobacter, 
Enterobacter, E. coli, Shigella, 
Serratia
Class C: AmpC-like Klebsiella, E. coli, Enterobacter, 
Pseudomonas, Acinetobacter
Class D: oxacillinases Pseudomonas, Acinetobacter, 
Enterobacter, Serratia
KPC, Klebsiella pneumoniae carbapenemase.
Table 2
Emergence of imipenem resistance during treatment of
Pseudomonas pneumonia
Treatment-emergent 
resistance 
Authors (year) [ref.] Daily dose (g) (n/total [%])
Salata et al. (1985) [36] 1.5 to 3 6/10 (60)
Quinn et al. (1986) [38]
Norrby et al. (1993) [35] 2 6/19 (32)
Cometta et al. (1994) [32] 2a 14/21 (67)
Fink et al. (1994) [33] 3 17/32 (53)
Jaccard et al. (1998) [34] 2 6/24 (25)
Zanetti et al. (2003) [37] 2 9/27 (33)
aSome patients also received 150 mg netilmicin twice a day.both decreased permeability and increased efflux [25,39]. As
a result, in vitro resistance selection occurs less frequently
with newer carbapenems than with imipenem [40,41]. Whether
this will translate into a clinically meaningful difference has
not been shown.
Future role of carbapenems
The future role of carbapenems will be governed by local
resistance patterns. Carbapenems are currently indicated for
the initial treatment of serious infections potentially caused by
MDR bacteria. They will retain this indication, whereas the
prevalence of resistance due to the production of ESBLs
exceeds that of resistance due to the production of KPCs
and metallo-β-carbapenemases. Infections caused by ESBL-
producing organisms are an increasing problem worldwide.
For example, the prevalence of K. pneumoniae producing
ESBLs has reached 50% in parts of Europe, and similar high
rates have been observed in Asia and Central and South
America [2]. Several groups have reported a reduction in
mortality after the early initiation of carbapenem therapy for
ESBL-producing organisms. In one evaluation [2] the 14-day
mortality rate in patients with bacteremia caused by ESBL-
producing K. pneumoniae was 5% in patients who received a
carbapenem early, as compared with 64% in patients whose
initial antibiotic regimen did not adequately cover ESBL-
producing organisms.
Although ESBL-producing organisms are typically thought of
as being hospital-acquired, these organisms have moved
beyond the hospital setting, and their prevalence in
community-acquired infections is also on the rise [42-44]. As
a result, carbapenems may play an increasingly important role
in the empiric emergency room treatment of serious com-
munity-acquired infections, particularly those involving the
urinary and gastrointestinal tracts or in immunocompromised
patients. Urinary tract infections caused by E. coli resistant to
trimethoprim-sulfamethoxazole and fluoroquinolones are no
longer uncommon [42]. In fact, a surveillance study conduc-
ted in 2006 reported a 20% rate of trimethoprim-sulfa-
methoxazole resistance in community-acquired urinary tract
infections in North America, and many of these organisms
were also resistant to cephalosporins [42].
Another potentially increased role for carbapenems is their
use in combination with aminoglycosides, cefepime, poly-
myxins, and/or rifampin in the treatment of MDR or pan-drug
resistant Gram-negative pathogens. As discussed above,
reduced permeability through the outer membrane is one of
the principal means by which Gram-negative pathogens
acquire resistance to carbapenems. Polymyxins increase
outer membrane permeability in these organisms, enhancing
carbapenem penetration [45], but their use clinically still
awaits controlled clinical studies. Numerous studies have
demonstrated the in vitro and clinical efficacy of combination
therapy against MDR pathogens, although some organisms
were not susceptible to the drugs when tested individually
(Table 3) [45-48]. For example, Yoon and colleagues [45]
evaluated eight isolates of Acinetobacter baumannii that
were resistant to imipenem alone. However, the combination
of imipenem with subinhibitory concentrations of polymyxin B
was bactericidal against seven of these isolates. The
combination of imipenem with polymyxin B and rifampin was
bactericidal against all eight isolates within 24 hours
(Figure 3) [45].
Furthermore, when the infecting organism is susceptible to
the antibiotic(s) being administered, adding an additional
agent may improve efficacy. In a randomized evaluation of
121 patients with bacteremia due to P. aeruginosa that was
susceptible to β-lactams and aminoglycosides [46], the
addition of rifampin to standard β-lactam plus aminoglycoside
therapy was associated with improvement in bacteriologic
cure rate compared with standard therapy (P = 0.018). The
potential beneficial effect of combination therapy may depend
on the prevalent mechanisms of resistance. For example,
adding polymyxin to carbapenem therapy should have a
positive effect against resistant Gram-negative pathogens
when the carbapenem resistance mechanism is reduced
permeability. This may not occur if the resistance mechanism
is carbapenemase production [45,49]. However, there are no
clinical data demonstrating that adding polymyxin to
carbapenem therapy has a positive effect. Suboptimal dosing
is a contributing factor to poor outcomes and the emergence
of resistance. Thus, antibiotics used in combination should
not be administered in reduced doses.
Finally, the future development of β-lactamase inhibitors
and/or efflux inhibitors may enhance and extend the utility of
the carbapenem class. Both Gram-positive and Gram-
negative organisms can express multidrug efflux pumps, and
almost all antibiotics are susceptible to the effects of these
pumps [50]. When they are used in combination with
antimicrobial agents, inhibitors of these pumps should
reverse resistance, enhancing the potency and expanding the
spectrum of activity of antimicrobial agents while decreasing
the emergence of new resistance [50]. The development of
clinically useful efflux inhibitors has proven to be problematic.
However, one candidate (MP-601,205; Mpex Pharmaceu-
ticals, San Diego, CA, USA) is undergoing phase I clinical
trials for the treatment of P. aeruginosa infections [50].
Likewise, the development of inhibitors of AmpC, KPC, or
metallo-β-lactamases may extend the life span of this class,
but progress has been slow [51].
Target pathogens
The majority of ESBL-producing enteric Gram-negative bacilli
are susceptible to carbapenem therapy and, because of co-
resistance, few other good treatment options remain for many
of these organisms [2,42,52]. In an evaluation of 312 ESBL-
producing Gram-negative bacilli recovered from patients at a
single urban teaching hospital [53], 75% were found to be
resistant to gentamicin, 70% to trimethoprim-sulfamethoxa-
Critical Care    Vol 12 Suppl 4 Rahal
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11% to amikacin, and 0% to imipenem. Likewise, in an
evaluation of 34 isolates of piperacillin-resistant P. aeru-
ginosa recovered from patients with VAP [21], 94% were
also resistant to ticarcillin-clavulanic acid, 91% to ticarcillin,
88% to piperacillin-tazobactam, 71% to ciprofloxacin, 62% to
ceftazidime, 59% to imipenem, and 50% to amikacin.
Because co-resistances will vary among institutions, know-
ledge of the local antibiogram is crucial in selecting
appropriate antimicrobial therapy for the target pathogen.
Carbapenems are effective in the treatment of susceptible
MDR Acinetobacter spp., with or without the addition of a
second active agent [52]. They are effective in the treatment
of susceptible P. aeruginosa when combined with a second
agent [13]. When used for this indication, follow-up cultures
are essential in order to detect the emergence of resistant
Pseudomonas. A recent meta-analysis of 12 randomized
controlled clinical trials of therapy for hospital-acquired
pneumonia in immunocompetent adults [54] showed
equivalence between carbapenems, fluoroquinolones, and β-
lactams, alone or in combination with aminoglycosides.
However, among a subset of patients with pneumonia due to
P. aeruginosa, carbapenem therapy was associated with
lower treatment success and pathogen eradication than
fluoroquinolones and β-lactams.
At New York Hospital Queens, KPC-producing Klebsiella
have become endemic. Thus, neutropenic patients with
serious hospital-acquired infection receive a five-drug
regimen to treat a wide variety of potential multiresistant
pathogens. This consists of polymyxin B, vancomycin,
rifampin, tigecycline, and a carbapenem. It is an aggressive
protocol but, as demonstrated by Kumar and colleagues [55],
time to the initiation of effective antimicrobial therapy is the
Available online http://ccforum.com/content/12/S4/S5
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Figure 3
Efficacy of combination therapy against multidrug resistant
Acinetobacter baumannii. cfu, colony forming units; Ctrl, control; IP,
imipenem; PB, polymyxin B; Pos, positive; RI, rifampin. Adapted with
permission [45]. Copyright © 2004 American Society for
Microbiology.single greatest predictor of survival in patients who develop
septic shock. In their study, a 1-hour delay in the initiation of
effective antibiotic therapy significantly increased in-hospital
mortality risk compared with initiation of such therapy within
the first hour (odds ratio 1.67, 95% confidence interval 1.12
to 2.48). Furthermore, this mortality risk continued to increase
for each additional hour of delay. During the initial 6-hour
period, overall survival fell by 7.6% for every hour that the
initiation of effective antibiotic therapy was delayed. Our
aggressive protocol is continuously updated as local
susceptibility patterns change. As yet, there are no controlled
clinical trial data to show that our current regimen is more
effective than others.
Conclusion
Achieving optimal results against serious bacterial infections
requires immediate, intensive antimicrobial therapy. Early
treatment should employ potent broad-spectrum agents in
order to increase the probability that this initial therapy will be
appropriate for the infecting pathogen. Carbapenems, often
in combination with other agents, remain a mainstay of this
early therapy in patients with serious hospital-acquired
infection. Further evolution of community-acquired ESBL-
producing organisms may broaden this indication to include
initial emergency room treatment of selected serious
infections. Initial empiric therapy should be re-evaluated and
adjusted once data from bacteriologic studies become
available. De-escalation to narrow-spectrum agents and the
use of short-course therapy, if appropriate for the infecting
pathogen, may help to limit the emergence of resistance.
However, short-term therapy should not be used against
nonfermenters such as P. aeruginosa. Finally, the pharmaco-
dynamics of antibiotics employed should always be
considered in order to achieve maximum dosing and the best
possible outcome. Such strategies may prolong the useful life
span of this valuable class of antibiotics.
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